GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal - Pharmaceutical Technology

HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, while sparing healthy tissue. HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, while sparing healthy tissue. GSK’s deal with HUTCHMED marks the latest in a long line of licensing activities between Western pharma companies and Chinese drug developers. Credit: testing/Shutterstock.com. GSK will pay a subsidiary of HUTCHMED $110m upfront for a novel type of drug designed to selectively target solid tumours. Under the licensing deal, a subsidiary of GSK will gain global rights to the cancer…

Source: Pharmaceutical Technology